Qingwei Geng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qingwei Geng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Bo Xie
Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital Zhejiang University School of Medicine Hangzhou China
1 shared publication- Cuiping Guan
Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China; Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China
1 shared publication Jinhui Xu
Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital Zhejiang University School of Medicine Hangzhou China
1 shared publication- Jun-Zhu Xu
Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou, China
1 shared publication Xiuzu Song
Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital Zhejiang University School of Medicine Hangzhou China
1 shared publicationYan Zhao
Department of Dermatology Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou China
1 shared publication
Latest Publications
- Open Access
- 4 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2556487
Abrocitinib combined with low-dose corticosteroids in the management of tattoo-related cutaneous sarcoidosis: a case report
Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a significant clinical challenge. We report the case of a 55-year-old female diagnosed with sarcoidosis. Skin and lymph node biopsies revealed non-caseating granulomatous inflammation, and chest CT indicated pulmonary involvement. Infectious causes of granulomatous disease, including Mycobacterium tuberculosis, non-tuberculous mycobacteria, and fungal infections, were excluded through com-prehensive testing. The patient initially received conventional systemic corticosteroid therapy but developed treatment-related complications. Due to the need for sustained disease control, an alternative regimen combining low-dose corticosteroids with the selective JAK1 inhibitor abrocitinib was initiated. The patient showed significant clinical improvement following the combination therapy, with no observed treatment-related adverse events. This case suggests that low-dose corticosteroids combined with a JAK1 inhibitor such as abrocitinib may represent a treatment option for patients with sarcoidosis.
- 4 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2556487
Open AccessAbrocitinib combined with low-dose corticosteroids in the management of tattoo-related cutaneous sarcoidosis: a case report
Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a significant clinical challenge. We report the case of a 55-year-old female diagnosed with sarcoidosis. Skin and lymph node biopsies revealed non-caseating granulomatous inflammation, and chest CT indicated pulmonary involvement. Infectious causes of granulomatous disease, including Mycobacterium tuberculosis, non-tuberculous mycobacteria, and fungal infections, were excluded through com-prehensive testing. The patient initially received conventional systemic corticosteroid therapy but developed treatment-related complications. Due to the need for sustained disease control, an alternative regimen combining low-dose corticosteroids with the selective JAK1 inhibitor abrocitinib was initiated. The patient showed significant clinical improvement following the combination therapy, with no observed treatment-related adverse events. This case suggests that low-dose corticosteroids combined with a JAK1 inhibitor such as abrocitinib may represent a treatment option for patients with sarcoidosis.
- 21 February 2023
- Published by Wiley in Experimental Dermatology
- Vol. 32 (6) , 777-786
Tranexamic acid may promote melanocores clustering in keratinocytes through upregulation of Rab5b
Tranexamic acid (TXA) is a promising therapeutic agent in melasma that can act on multiple pathophysiologic mechanisms of melasma. However, it is unclear whether TXA affects melanin in keratinocytes. To explore the effect of TXA on melanocores in keratinocytes. The melanocore‐incorporated keratinocytes were constructed by co‐incubating normal human epidermal keratinocytes (NHEK) with melanocores. After being treated with TXA, autophagy‐ and melanin‐related protein expressions were detected. Then, transcriptome sequencing was used to compare the genetic changes in melanocore‐incorporated keratinocytes before and after TXA treatment and further verified the differentially expressed genes. At the same time, the distribution of melanocores in human keratinocytes was observed by transmission electron microscopy. We found that TXA does not promote melanin degradation in primary keratinocytes by inducing autophagy. Protein transport and intracellular protein transport‐related genes were enriched after TXA treatment, and Rab5b was significantly upregulated. Transmission electron microscopy showed that the percentage of melanocores distributed in clusters increased after treatment with TXA, which was reduced after Rab5b silencing. In addition, results suggested that melanocores could colocalize with Rab5b and lysosome‐associated membrane protein1 (LAMP1). Our study found that Rab5b may be involved in the melanocore distribution in keratinocytes. TXA may promote the clustering distribution of endocytic melanocores through upregulation of Rab5b, representing a potential mechanism of TXA treatment against melasma.
- 21 February 2023
- Published by Wiley in Experimental Dermatology
- Vol. 32 (6) , 777-786
Tranexamic acid may promote melanocores clustering in keratinocytes through upregulation of Rab5b
Tranexamic acid (TXA) is a promising therapeutic agent in melasma that can act on multiple pathophysiologic mechanisms of melasma. However, it is unclear whether TXA affects melanin in keratinocytes. To explore the effect of TXA on melanocores in keratinocytes. The melanocore‐incorporated keratinocytes were constructed by co‐incubating normal human epidermal keratinocytes (NHEK) with melanocores. After being treated with TXA, autophagy‐ and melanin‐related protein expressions were detected. Then, transcriptome sequencing was used to compare the genetic changes in melanocore‐incorporated keratinocytes before and after TXA treatment and further verified the differentially expressed genes. At the same time, the distribution of melanocores in human keratinocytes was observed by transmission electron microscopy. We found that TXA does not promote melanin degradation in primary keratinocytes by inducing autophagy. Protein transport and intracellular protein transport‐related genes were enriched after TXA treatment, and Rab5b was significantly upregulated. Transmission electron microscopy showed that the percentage of melanocores distributed in clusters increased after treatment with TXA, which was reduced after Rab5b silencing. In addition, results suggested that melanocores could colocalize with Rab5b and lysosome‐associated membrane protein1 (LAMP1). Our study found that Rab5b may be involved in the melanocore distribution in keratinocytes. TXA may promote the clustering distribution of endocytic melanocores through upregulation of Rab5b, representing a potential mechanism of TXA treatment against melasma.